Equities

Burzynski Research Institute Inc

BZYR:PKC

Burzynski Research Institute Inc

Actions
  • Price (USD)0.043
  • Today's Change0.00 / 0.00%
  • Shares traded1.00
  • 1 Year change-39.82%
  • Beta1.0218
Data delayed at least 15 minutes, as of May 23 2024 14:30 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Burzynski Research Institute, Inc. is engaged in the research, production, marketing, promotion and sale of certain medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives and organic acids which are known under the trade name Antineoplastons. Antineoplastons are useful in the treatment of human cancer and are reviewing data from its Phase II clinical trials of Antineoplastons relating to the treatment of various cancers. Antineoplastons are found in the bodily fluids of humans and food. The Company conducted all the Phase II clinical trials for the treatment of a variety of cancers using the combination of Antineoplastons A10 and AS2-1. Most of the trials involve the use of intravenous formulations of Antineoplastons; however, a few trials use oral formulations. The Company has not generated any operating revenue since its inception. The Company's clinical trials are conducted at the Burzynski Clinic.

  • Revenue in USD (TTM)0.00
  • Net income in USD-1.34m
  • Incorporated1980
  • Employees2.00
  • Location
    Burzynski Research Institute Inc12000 Richmond AveHOUSTON 77082United StatesUSA
  • Phone+1 (713) 335-5697
  • Fax+1 (713) 935-0649
  • Websitehttp://burzynskiresearch.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Clever Leaves Holdings Inc17.42m-19.80m5.33m296.00--0.2169--0.3063-12.57-11.3811.1114.020.4181.6911.0358,841.21-47.51-23.20-58.14-26.5537.64---113.66-207.521.63-3.700.0479--6.14--47.63------
Halberd Corp281.24k25.34k5.40m3.003.66--213.0419.220.00230.00230.0018-0.00020.14490.03032.52--1.31--4.58--50.00--9.01--0.26611.351.02--271.52---60.11------
Hoth Therapeutics Inc0.00-7.70m5.52m2.00--0.6353-----2.02-2.020.001.780.00----0.00-70.17-157.07-77.15-177.32-----------50.670.00------31.01------
Applied DNA Sciences Inc5.52m-12.50m5.57m53.00------1.01-17.13-17.137.67-0.05580.389310.384.64104,110.80-87.15-88.57-111.09-121.9133.9844.35-223.89-113.261.54-------26.4327.92-18.73--33.80--
Burzynski Research Institute Inc0.00-1.34m5.65m2.00---------0.0102-0.01020.00-0.00020.00-------62,992.45-15,304.89-------------------------45.74------
Portage Biotech Inc0.00-144.90m5.74m7.00--0.1792-----7.96-7.960.001.620.00----0.00-111.60-19.70-113.27-26.48------------0.0087-------520.10------
Genprex Inc0.00-27.63m5.74m26.00--0.6005-----19.18-19.180.004.550.00----0.00-153.97-92.06-202.83-98.32------------0.00-------29.99---7.13--
Lixte Biotechnology Holdings Inc0.00-4.69m5.76m3.00---------2.38-2.380.001.390.00----0.00-118.45-104.18-130.17-111.05-----------1,253.200.00------19.41------
TFF Pharmaceuticals Inc885.71k-19.93m5.79m19.00--0.8881--6.54-10.20-10.200.43712.110.0647--3.7246,616.32-145.46-79.57-181.57-83.41-----2,249.83-8,687.66----0.00--48.01--33.13------
AiXin Life International Inc4.09m-2.09m5.82m207.00------1.42-0.0836-0.08360.1636-0.07650.82685.4310.0219,757.49-42.27-16.93---34.5416.2548.13-51.12-36.960.1515------51.0058.0867.18--194.59--
Kineta Inc5.16m-17.89m5.88m11.00------1.14-1.55-1.550.4673-0.5640.6667----469,181.80-230.51-66.16---86.61-----345.77-854.74--------178.6513.8977.76------
Creative Medical Technology Holdings Inc9.00k-5.28m5.93m4.00--0.6452--658.39-3.74-3.740.00646.810.00070.4291--2,250.00-42.47-110.00-43.88--60.0065.82-58,624.33-7,961.1423.53--0.00---89.84-40.8647.88------
Enveric Biosciences Inc0.00-15.11m5.93m7.00--0.8609-----6.46-6.460.000.88870.00----0.00-122.02-104.94-178.49-156.88-------243.54----0.00------7.14------
Pasithea Therapeutics Corp0.00-16.10m5.94m8.00--0.2985-----14.03-14.170.0019.060.00----0.00-49.97---53.80--------------0.00-------32.23------
Hepion Pharmaceuticals Inc0.00-38.52m5.99m22.00--1.03-----9.49-9.490.001.370.00----0.00-117.64-61.43-145.05-68.82-----------3,240.310.00-------7.92------
Data as of May 23 2024. Currency figures normalised to Burzynski Research Institute Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.